- Home
- SBSI vs TSHA Comparison
SBSI vs TSHA Comparison
Compare SBSI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSI
- TSHA
- Stock Information
- Founded
- SBSI 1960
- TSHA 2019
- Country
- SBSI United States
- TSHA United States
- Employees
- SBSI N/A
- TSHA N/A
- Industry
- SBSI Major Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- SBSI Finance
- TSHA Health Care
- Exchange
- SBSI Nasdaq
- TSHA Nasdaq
- Market Cap
- SBSI 874.1M
- TSHA 728.4M
- IPO Year
- SBSI N/A
- TSHA 2020
- Fundamental
- Price
- SBSI $31.20
- TSHA $2.45
- Analyst Decision
- SBSI Hold
- TSHA Strong Buy
- Analyst Count
- SBSI 2
- TSHA 5
- Target Price
- SBSI $37.00
- TSHA $8.20
- AVG Volume (30 Days)
- SBSI 126.4K
- TSHA 3.4M
- Earning Date
- SBSI 07-24-2025
- TSHA 08-11-2025
- Dividend Yield
- SBSI 4.68%
- TSHA N/A
- EPS Growth
- SBSI 7.94
- TSHA N/A
- EPS
- SBSI 2.91
- TSHA N/A
- Revenue
- SBSI $254,817,000.00
- TSHA $7,224,000.00
- Revenue This Year
- SBSI $10.28
- TSHA N/A
- Revenue Next Year
- SBSI $5.20
- TSHA N/A
- P/E Ratio
- SBSI $10.72
- TSHA N/A
- Revenue Growth
- SBSI 6.49
- TSHA N/A
- 52 Week Low
- SBSI $25.85
- TSHA $1.05
- 52 Week High
- SBSI $38.00
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- SBSI 74.42
- TSHA 48.54
- Support Level
- SBSI $29.20
- TSHA $2.25
- Resistance Level
- SBSI $29.48
- TSHA $2.51
- Average True Range (ATR)
- SBSI 0.56
- TSHA 0.15
- MACD
- SBSI 0.30
- TSHA -0.03
- Stochastic Oscillator
- SBSI 97.67
- TSHA 48.78
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.